NCT04218071View on ClinicalTrials.gov

Actuate 1901: 9-ING-41 in Myelofibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 20, 2020

Primary Completion Date

October 13, 2022

Study Completion Date

January 18, 2024

Conditions
Myelofibrosis
Interventions
DRUG

Ruxolitinib

Ruxolitinib at protocol-specified doses for given platelet count

DRUG

9-ING-41

9-

Trial Locations (9)

27710

Duke Cancer Center, Durham

30912

Georgia Cancer Center, Augusta

55905

Mayo Clinic, Rochester

63100

Siteman Cancer Center, St Louis

90033

University of Southern California, Los Angeles

90095

University of California Los Angeles, Los Angeles

98109

Fred Hutchinson Cancer Research Center, Seattle

New York

"Weill Cornell Medicine , NewYork-Presbyterian Meyer Cancer Center"

02912

Brown University, Providence

Sponsors
All Listed Sponsors
lead

Actuate Therapeutics Inc.

INDUSTRY

NCT04218071 - Actuate 1901: 9-ING-41 in Myelofibrosis | Biotech Hunter | Biotech Hunter